Global ETD Search

1	Conception, synthèse et évaluation biologique d’inhibiteurs de PfA-M17, potentielle cible antipaludéenne / Design, synthesis and evaluation of PfA-M17 inhibitors, a potential antimalarial target Chaillou, Bérénice 30 October 2015 (has links) Le paludisme, maladie infectieuse due à des parasites du genre Plasmodium, reste mortel et préoccupant dans les régions intertropicales d’Afrique, d’Asie et d’Amérique. Les phénomènes de résistance des parasites aux différentes générations de traitements représentent un problème majeur, auxquels s’ajoutent le coût des traitements et donc l’accès aux soins pour les populations les plus défavorisées. Il est ainsi urgent de trouver de nouvelles cibles et de développer de nouveaux agents antipaludiques agissant via des mécanismes originaux. La cible étudiée lors de ces travaux de thèse est la leucyl aminopeptidase bimétallique de P. falciparum, notée PfA-M17. Elle a récemment émergé comme potentielle cible antipaludéenne et jouerait un rôle essentiel à la croissance et à la survie du parasite. Elle serait impliquée dans la dernière étape du catabolisme de l’hémoglobine lors du cycle érythrocytaire du parasite. Ces travaux se sont concentrés sur la conception, la synthèse et l’évaluation d’inhibiteurs sélectifs de PfA-M17. En s’inspirant de travaux antérieurs menés au laboratoire et d’expériences de modélisation moléculaire, des analogues benzocycloheptanes trisubstitués ont été conçus pour inhiber sélectivement PfA-M17. Une voie de synthèse diastéréosélective partant de l’acide D-isoascorbique a été mise au point et a permis d’accéder à des analogues cycloheptanes et cyclohexanes trisubstitués. Cette voie de synthèse a aussi été étudiée afin d’obtenir des analogues benzocycloheptanes trisubstitués. / Malaria is an infectious disease due to Plasmodium parasites, still causing numerous deaths in intertropical areas of Africa, America and Asia. Existing treatments face problems of high cost and resistance, hence the need to discover new targets and to develop new compounds. This work focused on a recent antimalarial target, a bimetallic leucyl aminopeptidase, named PfA-M17. Inhibition of this aminopeptidase shows it is essential for parasite survival and growth. PfA-M17 may be involved in the last step of hemoglobin digestion during the intraerythrocytic cycle of the parasite. This study concerned the design, the synthesis and the evaluation of selective PfA-M17 inhibitors. Trisubstituted benzocycloheptane analogs were designed as PfA-M17 inhibitors, based on previous works performed in our team and based on molecular modelling. A diastereoselective pathway was developed from D-isoascorbic acid and gave trisubstituted cycloheptanes and cyclohexanes analogs. This pathway was also studied in order to get the trisubstituted benzocycloheptane scaffolds. Leucyl aminopeptidase PfA-M17 Paludisme Inhibiteurs de métalloaminopeptidase PfA-M17 leucyl aminopeptidase Malaria Metalloaminopeptidase Inhibitors Trisubstituted benzocycloheptane analogs 547
2	Corticotropin Releasing Factor up-Regulates the Expression and Function of Norepinephrine Transporter in SK-N-Be (2) m17 Cells Huang, Jingjing, Tufan, Turan, Deng, Maoxian, Wright, Gary, Zhu, Meng Yang 01 October 2015 (has links) Corticotropin releasing factor (CRF) has been implicated to act as a neurotransmitter or modulator in central nervous activation during stress. In this study, we examined the regulatory effect of CRF on the expression and function of the norepinephrine transporter (NET) in vitro. SK-N-BE (2) M17 cells were exposed to different concentrations of CRF for different periods. Results showed that exposure of cells to CRF significantly increased mRNA and protein levels of NET in a concentration- and time-dependent manner. The CRF-induced increase in NET expression was mimicked by agonists of either CRF receptor 1 or 2. Furthermore, similar CRF treatments induced a parallel increase in the uptake of [3H] norepinephrine. Both increased expression and function of NET caused by CRF were abolished by simultaneous administration of CRF receptor antagonists, indicating a mediation by CRF receptors. However, there was no additive effect for the combination of both receptor antagonists. Chromatin immunoprecipitation assays confirm an increased acetylation of histone H3 on the NET promoter following treatment with CRF. Taken together, this study demonstrates that CRF up-regulates the expression and function of NET in vitro. This regulation is mediated through CRF receptors and an epigenetic mechanism related to histone acetylation may be involved. This CRF-induced regulation on NET expression and function may play a role in development of stress-related depression and anxiety. This study demonstrated that corticotropin release factor (CRF) up-regulated the expression and function of norepinephrine transporter (NET) in a concentration- and time-dependent manner, through activation of CRF receptors and possible histone acetylation in NET promoter. The results indicate that their interaction may play an important role in stress-related physiological and pathological status. This study demonstrated that corticotropin release factor (CRF) up-regulated the expression and function of norepinephrine transporter (NET) in a concentration- and time-dependent manner, through activation of CRF receptors and possible histone acetylation in NET promoter. The results indicate that their interaction may play an important role in stress-related physiological and pathological status. corticotropin release factor gene regulation noradrenergic neurons norepinephrine transporter SK-N-BE(2)M17 cells Biomedical Sciences
3	Development and Validation of Novel Polymer-based DNA Delivery Systems for Effective and Affordable Non-viral Gene Therapies Zhang, Jun 23 May 2022 (has links) No description available. Animal Diseases Biochemistry Biology Biomedical Engineering Biomedical Research Cellular Biology Developmental Biology Engineering Environmental Health Health Health Sciences Immunology Materials Science Medicine Molecular Biology Molecules Nanoscience Nanotechnology Neurobiology Neurology Neurosciences Organic Chemistry Pharmaceuticals Pharmacy Sciences Polymer Chemistry Polymers Public Health Toxicology Therapy Virology gene therapy gene delivery DNA delivery polymer non-viral nonviral therapeutic polyethylenimine PEI in vitro in vivo C2C12 muscle muscular M17 neuro neural brain transfection cell penetrating peptide neurodegenerative Alzheimer Parkinson prion PrP N1 C1 amyloid-β Aβ Tau α-synuclein αSyn α-cleavage ADAM8 pscAAV

1

Page generated in 0.0419 seconds